J Korean Assoc Oral Maxillofac Surg.  2018 Oct;44(5):220-224. 10.5125/jkaoms.2018.44.5.220.

Metachronous second primary malignancy in head and neck cancer patients: is five years of follow-up sufficient?

• Adeel M
• Siddiqi MI

• KMID: 2430582
• DOI: http://doi.org/10.5125/jkaoms.2018.44.5.220

Abstract

OBJECTIVES
The aim of this study was to determine the incidence and characteristics of second primary malignancy (SPM) in patients with head and neck squamous cell carcinoma treated at a tertiary care hospital.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 221 patients who underwent surgery with or without adjuvant treatment for head and neck cancer from 2000 to 2002. Data of age, sex, risk factors, sites of primary and SPM, TNM stage of primary tumor, incidence of SPM, and survival were collected from medical charts.
RESULTS
Eighteen patients developed SPM during a median follow-up of 67 months, with an overall incidence of 8.14%. In addition, 77.7% of SPMs occurred in the oral cavity, followed by 11% in the lungs. The 5-year overall survival after the diagnosis of SPM in the head or neck was 70%, compared to 30% for SPM in other body regions.
CONCLUSION
Considering a high incidence of SPM, i.e., 8.14%, in a mean follow-up period of 67 months suggests the need for long-term follow-up. Since treatment of SPM has shown an acceptable survival rate, early detection and curative therapy should be emphasized.

Keyword

Second primary malignancy; Survivorship; Survival rate

MeSH Terms

Body Regions
Carcinoma, Squamous Cell
Diagnosis
Follow-Up Studies*
Head and Neck Neoplasms*
Head*
Humans
Incidence
Lung
Medical Records
Mouth
Neck
Retrospective Studies
Risk Factors
Survival Rate
Tertiary Healthcare

Figure

• 

  Fig. 1 Survival functions. (SPM: second primary malignancy)

Reference

1. Chu PY, Chang SY, Huang JL, Tai SK. Different patterns of second primary malignancy in patients with squamous cell carcinoma of larynx and hypopharynx. Am J Otolaryngol. 2010; 31:168–174.

2. Fujisawa R, Shibuya H, Harata N, Yuasa-Nakagawa K, Toda K, Hayashi K. Chronological shifts and changing causes of death after radiotherapy for early-stage oral cancer. Int J Clin Oncol. 2014; 19:24–29.

3. Schwartz LH, Ozsahin M, Zhang GN, Touboul E, De Vataire F, Andolenko P, et al. Synchronous and metachronous head and neck carcinomas. Cancer. 1994; 74:1933–1938.

4. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys. 1989; 17:449–456.

5. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys. 1989; 17:691–694.

6. Vikram B, Strong EW, Shah JP, Spiro R. Second malignant neoplasms in patients successfully treated with multimodality treatment for advanced head and neck cancer. Head Neck Surg. 1984; 6:734–737.

7. Warren S. Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer. 1932; 16:1358–1414.

8. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990; 323:795–801.

9. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17:1471–1474.

10. León X, del Prado Venegas M, Orús C, Kolañczak K, García J, Quer M. Metachronous second primary tumours in the aerodigestive tract in patients with early stage head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2005; 262:905–909.

11. León X, Ferlito A, Myer CM 3rd, Saffiotti U, Shaha AR, Bradley PJ, et al. Second primary tumors in head and neck cancer patients. Acta Otolaryngol. 2002; 122:765–778.

12. León X, Quer M, Orús C, del Prado, López M. Distant metastases in head and neck cancer patients who achieved locoregional control. Head Neck. 2000; 22:680–686.

13. León X, Quer M, Diez S, Orús C, López-Pousa A, Burgués J. Second neoplasm in patients with head and neck cancer. Head Neck. 1999; 21:204–210.

14. Dikshit RP, Boffetta P, Bouchardy C, Merletti F, Crosignani P, Cuchi T, et al. Risk factors for the development of second primary tumors among men after laryngeal and hypopharyngeal carcinoma. Cancer. 2005; 103:2326–2333.

15. Mehdi I, Shah AH, Moona MS, Verma K, Abussa A, Elramih R, et al. Synchronous and metachronous maligant tumours expect the unexpected. J Pak Med Assoc. 2010; 60:905–909.

16. Hong WK, Bromer RH, Amato DA, Shapshay S, Vincent M, Vaughan C, et al. Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer. 1985; 56:1242–1245.

17. Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol. 1995; 104:946–954.

18. Chen JY, Chang YL, Yu YC, Chao CC, Kao HW, Wu CT, et al. Specific induction of the high-molecular-weight microtubule-associated protein 2 (hmw-MAP2) by betel quid extract in cultured oral keratinocytes: clinical implications in betel quid-associated oral squamous cell carcinoma (OSCC). Carcinogenesis. 2004; 25:269–276.

19. Ećimović P, Pompe-Kirn V. Second primary cancers in laryngeal cancer patients in Slovenia, 1961-1996. Eur J Cancer. 2002; 38:1254–1260.

20. Hsu YB, Chang SY, Lan MC, Huang JL, Tai SK, Chu PY. Second primary malignancies in squamous cell carcinomas of the tongue and larynx: an analysis of incidence, pattern, and outcome. J Chin Med Assoc. 2008; 71:86–91.

21. Di Martino E, Sellhaus B, Hausmann R, Minkenberg R, Lohmann M, Esthofen MW. Survival in second primary malignancies of patients with head and neck cancer. J Laryngol Otol. 2002; 116:831–838.